LEO Pharma Reports Positive Phase 2 Tralokinumab Results
BALLERUP, Denmark, July 9, 2026 LEO Pharma A/S has announced positive results from the Phase 2 TRAPEDS-1 clinical trial...
Merck
Advertisement
Merck Announces Expanded FDA Approval for Keytruda in MIBC
SILVER SPRING, Maryland, July 10, 2026 Merck has received U.S. Food and Drug Administration (FDA) approval for Keytruda® (pembrolizumab)...
Merck’s CAPVAXIVE Wins FDA Approval for High-Risk Children
RAHWAY, N.J., June 18, 2026 Merck announced that the U.S. Food and Drug Administration (FDA) has approved an expanded...
Protillion Biosciences Partners With Merck on AI Drug Discovery
CARLSBAD, Calif., June 16, 2026 Protillion Biosciences has announced a significant multi-target drug discovery collaboration and license agreement with...
Merck and Gilead End KEYNOTE-D46 Study Update
RAHWAY, N.J. and FOSTER CITY, Calif., June 8, 2026 Merck (NYSE: MRK) and Gilead Sciences (Nasdaq: GILD) announced the...
Advertisements
Merck’s KEYTRUDA and Padcev Combination Shows Strong Survival Benefit Ahead of EU Approval
RAHWAY, New Jersey, May 24, 2026 Merck announced that the European Medicines Agency’s Committee for Medicinal Products for Human...
Merck Sac-TMT Trial Shows Survival Benefit in Cancer
Rahway, N.J., USA – May 18, 2026 Merck announced that its pivotal Phase 3 TroFuse-005 clinical trial evaluating sacituzumab...
Discovery Life Sciences Launches Luminos for Faster EU Oncology Trials
HUNTSVILLE, Ala. and KASSEL, Germany, May 20, 2026 Discovery Life Sciences has launched Luminos® Comprehensive, a next-generation IVDR-compliant clinical...
Scinai Appoints Eilon Elmalem to Lead Yavne CDMO
JERUSALEM, Israel, May 20, 2026 Scinai Immunotherapeutics Ltd. has announced the appointment of Eilon Elmalem as the new Site...
Merck Unveils Major Oncology Advances at ASCO 2026
RAHWAY, N.J., May 12, 2026 Merck announced a major expansion of its oncology research portfolio ahead of the 2026...
Advertisement
